Gilles Degotte

Dr. Gilles Degotte

University of Reims Champagne-Ardenne, Reims, Grand Est, France
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 April 2025 in Science Advances
Verified
Journal Article
Open access
TDTyler Detomasi
Tyler Detomasi
Gilles DegotteGilles Degotte
Gilles Degotte
SHSijie Huang
Sijie Huang
RSRahul K. Suryawanshi
Rahul K. Suryawanshi
ADAmy Diallo
Amy Diallo
CCCharles Craik
Charles Craik
The main protease (M Pro ) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a validated drug target. Starting with a lead-like dihydrouracil chemotype identified in a large-library docking campaign, we improved M Pro inhibition >1000-fold by engaging additional M Pro subsites and using a latent electrophile to engage Cys 145 . Advanced leads from this series show pan-coronavirus antiviral activity, low clearance in mice, and for AVI-4773 , a rapid reduction in viral titers >1,000,000 after just three doses. Both compounds are well distributed in mouse tissues, including brain, where concentrations >1000× the 90% effective concentration are observed 8 hours after oral dosing for AVI-4773 . AVI-4516 shows minimal inhibition of major cytochrome P450s and human proteases. AVI-4516 also exhibits synergy with the RNA-dependent RNA polymerase inhibitor, molnupiravir, in cellular infection models. Related analogs strongly inhibit nirmatrelvir-resistant M Pro mutant virus. The properties of this chemotype are differentiated from existing clinical and preclinical M Pro inhibitors and will advance therapeutic development against emerging SARS-CoV-2 variants and other coronaviruses.

4 August 2021 in Archiv der Pharmazie
Verified
Journal Article
Closed access
PDF file
Gilles DegotteGilles Degotte
Gilles Degotte
BPBernard Pirotte
Bernard Pirotte
Michel FREDERICHMichel FREDERICH
Michel FREDERICH
PFPierre Francotte
Pierre Francotte

2 June 2023 in Molecules
Verified
Journal Article
Open access
PDF file
Gilles DegotteGilles Degotte
Gilles Degotte
Michel FREDERICHMichel FREDERICH
Michel FREDERICH
PFPierre Francotte
Pierre Francotte
TFThierry Franck
Thierry Franck
TCThomas Colson
Thomas Colson
AMAnge Mouithys-Mickalad
Ange Mouithys-Mickalad
Malaria is an infectious disease caused by a Plasmodium genus parasite that remains the most widespread parasitosis. The spread of Plasmodium clones that are increasingly resistant to antimalarial molecules is a serious public health problem for underdeveloped countries. Therefore, the search for new therapeutic approaches is necessary. For example, one strategy could consist of studying the redox process involved in the development of the parasite. Regarding potential drug candidates, ellagic acid is widely studied due to its antioxidant and parasite-inhibiting properties. However, its low oral bioavailability remains a concern and has led to pharmacomodulation and the synthesis of new polyphenolic compounds to improve antimalarial activity. This work aimed at investigating the modulatory effect of ellagic acid and its analogues on the redox activity of neutrophils and myeloperoxidase involved in malaria. Overall, the compounds show an inhibitory effect on free radicals as well as on the enzyme horseradish peroxidase- and myeloperoxidase (HRP/MPO)-catalyzed oxidation of substrates (L-012 and Amplex Red). Similar results are obtained with reactive oxygen species (ROS) produced by phorbol 12-mystate acetate (PMA)-activated neutrophils. The efficiency of ellagic acid analogues will be discussed in terms of structure–activity relationships.

12 November 2022 in Molecules
Verified
Journal Article
Open access
PDF file
JKJiri Kos
Jiri Kos
Gilles DegotteGilles Degotte
Gilles Degotte
DPDominika Pindjaková
Dominika Pindjaková
TSTomáš Strhársky
Tomáš Strhársky
TJTimotej Jankech
Timotej Jankech
Josef JampilekJosef Jampilek
Josef Jampilek
Due to the urgent need of innovation in the antimalarial therapeutic arsenal, a series of thirty-seven ring-substituted N-arylcinnamanilides prepared by microwave-assisted synthesis were subjected to primary screening against the chloroquine-sensitive strain of P. falciparum 3D7/MRA-102. The lipophilicity of all compounds was experimentally determined as the logarithm of the capacity factor k, and these data were subsequently used in the discussion of structure-activity relationships. Among the screened compounds, fourteen derivatives exhibited IC50 from 0.58 to 31 µM, whereas (2E)-N-(4-bromo-2-chlorophenyl)-3-phenylprop-2-enamide (24) was the most effective agent (IC50 = 0.58 µM). In addition, (2E)-N-[2,6-dibromo-4-(trifluoromethyl)- phenyl]-3-phenylprop-2-enamide (36), (2E)-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-phenylprop- 2-enamide (18), (2E)-N-(2-bromo-5-fluorophenyl)-3-phenylprop-2-enamide (23), and (2E)-3-phenyl-N-(3,4,5-trichlorophenyl)prop-2-enamide (33) demonstrated efficacy in the IC50 range from 2.0 to 4.3 µM, comparable to the clinically used standard chloroquine. The results of a cell viability screening performed using THP1-Blue™ NF-κB cells showed that none of these highly active compounds displayed any significant cytotoxic effect up to 20 μM, which makes them promising Plasmodium selective substances for further investigations.

10 February 2023 in RSC Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
Gilles DegotteGilles Degotte
Gilles Degotte
HPHélène Pendeville
Hélène Pendeville
CCCarla Di Chio
Carla Di Chio
RERoberta Ettari
Roberta Ettari
BPBernard Pirotte
Bernard Pirotte
PFPierre Francotte
Pierre Francotte
A polyphenolic scaffold to develop novel orally active antimalarials against resistant Plasmodium falciparum.

17 September 2021 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
Gilles DegotteGilles Degotte
Gilles Degotte
BPBernard Pirotte
Bernard Pirotte
PFPierre Francotte
Pierre Francotte
Michel FREDERICHMichel FREDERICH
Michel FREDERICH
Background: Despite major advances in the fight against this parasitic disease, malaria remained a major cause of concern in 2021. This infection, mainly due to Plasmodium falciparum, causes more than 200 million cases every year and hundreds of thousands deaths in the developing regions, mostly in Africa. The last statistics show an increase in the cases for the third consecutive year; from 211 million in 2015, it has reached 229 million in 2019. This trend could be partially explained by the appearance of resistance to all the used antimalarials, including artemisinin. Thus, the design of new anti- Plasmodium compounds is an urgent need. For thousands of years, nature has offered humans medicines to cure their diseases or the inspiration for the development of new active principles. It then seems logical to explore the natural sources to find new molecules to treat this parasitosis. Methods: Therefore, this review reports and analyzes the extracts (plants, bacteria, sponges, fungi) and the corresponding isolated compounds, showing antiplasmodial properties between 2013 and 2019. Results & Conclusion: Nature remains a major source of active compounds. Indeed, 648 molecules from various origins, mostly plants, have been reported for their inhibitory effect on Plasmodium falciparum. Among them, 188 scaffolds were defined as highly active with IC50 ≤ 5 μM, and have been reported here in detail. Moreover, the most active compounds showed a large variety of structures, such as flavonoids, triterpenes, and alkaloids. Therefore, these compounds could be an interesting source of inspiration for medicinal chemists; several of these molecules could become the next leads for malaria treatment.